Zeo ScientifiX Amends Bylaws, Fiscal Year
Ticker: ZEOX · Form: 8-K · Filed: Feb 26, 2024 · CIK: 1557376
Sentiment: neutral
Topics: corporate-governance, bylaw-amendment, fiscal-year-change
TL;DR
**Zeo ScientifiX just changed its corporate rules and possibly its financial reporting calendar, watch for details!**
AI Summary
Zeo ScientifiX, Inc. (formerly Organicell Regenerative Medicine, Inc.) filed an 8-K on February 26, 2024, reporting an event on February 20, 2024, related to amendments to its Articles of Incorporation or Bylaws and changes in its fiscal year. The company, based in Davie, FL, with CIK 0001557376, operates in the biological products industry. This filing indicates potential corporate governance or structural changes within the company.
Why It Matters
Changes to a company's articles of incorporation or bylaws can impact shareholder rights and corporate governance, while a fiscal year change can affect financial reporting schedules.
Risk Assessment
Risk Level: medium — Changes to corporate governance documents can sometimes signal significant strategic shifts or attempts to consolidate control, which could be positive or negative depending on the specifics.
Key Players & Entities
- Zeo ScientifiX, Inc. (company) — Registrant
- Organicell Regenerative Medicine, Inc. (company) — Former company name
- February 20, 2024 (date) — Date of earliest event reported
- February 26, 2024 (date) — Filing date
- 0001557376 (company) — Central Index Key (CIK)
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported was on February 20, 2024.
What specific items were reported in this 8-K?
The 8-K reported 'Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year' and 'Financial Statements and Exhibits'.
What is the Central Index Key (CIK) for Zeo ScientifiX, Inc.?
The CIK for Zeo ScientifiX, Inc. is 0001557376.
What was the previous name of Zeo ScientifiX, Inc. before its current name?
One of the former names of Zeo ScientifiX, Inc. was Organicell Regenerative Medicine, Inc., with a name change date of 20180625.
Where is Zeo ScientifiX, Inc.'s business address located?
Zeo ScientifiX, Inc.'s business address is 3321 College Avenue, Suite 246, Davie, FL 33314.
Filing Stats: 548 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-02-26 16:05:29
Filing Documents
- zeoscientifixinc_8k.htm (8-K) — 29KB
- zeoscientifixinc_ex3-1.htm (EX-3.1) — 9KB
- ex3-1_001.jpg (GRAPHIC) — 480KB
- ex3-1_002.jpg (GRAPHIC) — 873KB
- ex3-1_003.jpg (GRAPHIC) — 658KB
- ex3-1_004.jpg (GRAPHIC) — 697KB
- 0001829126-24-001107.txt ( ) — 3821KB
- ocel-20240220.xsd (EX-101.SCH) — 3KB
- ocel-20240220_lab.xml (EX-101.LAB) — 33KB
- ocel-20240220_pre.xml (EX-101.PRE) — 22KB
- zeoscientifixinc_8k_htm.xml (XML) — 3KB
03 Amendments
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. The Company has filed an Amendment to its Articles of Incorporation (the " Amendment ") with the Secretary of State of Nevada, changing its name from " Organicell Regenerative Medicine, Inc. " to " Zeo ScientifiX, Inc. " effective February 20, 2024. The filing was made in connection with the review and processing of our Issuer Company-Related Action Notification Form (the " Notification "), which was submitted to the Financial Industry Regulatory Authority (" FINRA ") with respect to the name change and a corresponding change in our trading symbol. FINRA has not as yet completed its review of the Notification and assigned us a new trading symbol.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 3.1 Articles of Amendment to Articles of Incorporation of Organicell Regenerative Medicine, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: February 26, 2024 ZEO SCIENTIFIX, INC. By: /s/ Harry Leider Harry Leider, M.D. Chief Executive Officer 2